Search

Displaying results 951 - 960 of 10000 in total
  1. Drug

    Formoterol

    go.drugbank.com/drugs/DB00983
    ApprovedInvestigational

    Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. … [A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration

    Mixtures: FLUTIFORM® 125 MCG / 5 MCG, FLUTIFORM® 125 MCG / 5 MCGCategories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic Agonists
  2. Drug

    Dequalinium

    go.drugbank.com/drugs/DB04209
    Approved

    [A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. … [A249255] First used as an antiseptic and disinfectant in the 1950s, dequalinium is still found in various OTC products to treat conditions of oral infections and inflammation.

    Mixtures: EFISOL-C, JASIMENTH C PASTILLESCategories: Heterocyclic Compounds, 2-Ring
  3. Drug

    Vecuronium

    go.drugbank.com/drugs/DB01339
    ApprovedInvestigational

    A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. … Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or

    Categories: P-glycoprotein substratesProducts: VECURON INYECCION 2 ML (VECURONIO BROMURO 4 MG/ AMPOLLA), VECURONIO BROMURO 10 MG /2.5 ML POLVO LIOFILIZADO PARA SOLUCION INYECTABLE
  4. Drug

    Bromhexine

    go.drugbank.com/drugs/DB09019
    ApprovedInvestigational

    Bromhexine is mucolytic agent used for a variety of respiratory conditions associated with increased mucus secretion. … It was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries.

    Mixtures: BRONCODEX JARABE (GUAIFENESIN 2 G + BROMHEXINA HCI 0.08 G), GLICERTOX N FSynonyms: N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine, 3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine
  5. Drug

    Sodium fluorophosphate

    go.drugbank.com/drugs/DB09484
    ApprovedInvestigational

    Sodium monofluorophosphate is used in OTC dental preparations to help protect against cavities.

    Mixtures: Ron 2, FLUOCALCIC EFERVESAN TABLET, 20 ADETCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Naphazoline

    go.drugbank.com/drugs/DB06711
    Approved

    Naphazoline was first developed in 1942 as a nasal formulation for congestion[A176609]. … Naphazoline is a rapid acting imidazoline sympathomimetic vasoconstrictor of ocular or nasal artierioles[L5804,L5807].

    Mixtures: SULFARHIN BURUN MERHEMI, 20 G, OSMOCROM-N ®Categories: Adrenergic alpha-2 Receptor Agonists, Heterocyclic Compounds, 1-Ring
  7. Drug

    PRX-ASL

    go.drugbank.com/drugs/DB17679
    Experimental

    PRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.

    Synonyms: PRX ASL, PRX-ASL
  8. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor.

    Mixtures: CHAMPIX 0,5 MG 1 MG FILM KAPLI TABLET, 11 VE 14 ADET, CHAMPIX 0,5 MG 1 MG FILM KAPLI TABLET, 11 VE 14 ADETCategories: Heterocyclic Compounds, 2-Ring, Drugs Used in Addictive Disorders
  9. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  10. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    apo B-containing lipoproteins in the liver and intestines. … [A7367] Lomitapide was first approved by the FDA in December 2012 and the EMA in July 2013 as an adjunct to a low-fat diet and other lipid-lowering treatments.[A275444, A275446]

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDE